Abstract
AbstractDrug‐based mixed‐ligand copper(II) complexes of type [Cu(OFL)(An)Cl]·5H2O (OFL = ofloxacin, A1 = pyridine‐2‐carbaldehyde, A2 = 2,2′‐bipyridylamine, A3 = thiophene‐2‐carbaldehyde, A4 = 2,9‐dimethyl‐1,10‐phenanthroline, A5 = 2,9‐dimethyl‐4,7‐diphenyl‐1,10‐phenanthroline, A6 = 4,5‐diazafluoren‐9‐one, A7 = 1,10‐phenanthroline‐5,6‐dione and A8 = 5‐nitro‐1,10‐phenanthroline) were synthesized and characterized. Spectral investigations of complexes revealed square pyramidal geometry. Viscosity measurement and absorption titration were employed to determine the mode of binding of complexes with DNA. DNA cleavage study showed better cleaving ability of the complexes compared with metal salt and standard drug by conversion of a supercoiled form of pUC19 DNA to linear via circular. From the SOD mimic study, concentration of complexes ranging from 0.415 to 1.305 µM is enough to inhibit the reduction rate of NBT by 50% (IC50) in the NADH‐PMS system. Antibacterial activity was assayed against selective Gram‐negative and Gram‐positive microorganisms using the doubling dilution technique. Copyright © 2010 John Wiley & Sons, Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
